Blog | HemaCare

HemaCare Aids Strategy for Boosting Gene Therapy Efficiency

May 21, 2019 10:06:00 AM / by Nancy Andon, MSc posted in Gene Therapy, bone marrow stem cells, CD34, Stem Cells, mobilized peripheral blood

0 Comments

An independent publication cites the use of bone marrow and mobilized peripheral blood sourced from HemaCare in a study aimed at improving the efficiency of resource consumption in gene therapy.

The publication, published in the journal Molecular Therapy, focuses on the use of lentiviral vector (LV) to introduce corrected versions of defective genes into stem cells. The goal of gene therapy is to transplant these stem cells into people suffering from genetic disease, in hopes of restoring the function of the faulty gene. One of the main challenges in this clinical strategy is the cost; substantial amounts of LV are needed to modify a therapeutically effective dose of stem cells.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts